AbbVie Inc (ABBV)vsBausch + Lomb Corp (BLCO)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
BLCO
Bausch + Lomb Corp
$16.18
+1.70%
HEALTHCARE · Cap: $5.67B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1132% more annual revenue ($62.82B vs $5.10B). ABBV leads profitability with a 5.8% profit margin vs -7.1%. ABBV appears more attractively valued with a PEG of 0.57. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
BLCO
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-20.5%
Fair Value
$168.19
Current Price
$201.55
$33.36 premium
Margin of Safety
+57.6%
Fair Value
$40.13
Current Price
$16.18
$23.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Weak financial health signals
ROE of -5.4% — below average capital efficiency
Earnings declined 88.6%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : BLCO
The strongest argument for BLCO centers on Price/Book, PEG Ratio. PEG of 0.89 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : BLCO
The primary concerns for BLCO are Piotroski F-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while BLCO is a turnaround play — different risk/reward profiles.
BLCO carries more volatility with a beta of 0.59 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 47/100) and 12.4% revenue growth. BLCO offers better value entry with a 57.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Bausch + Lomb Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Bausch Lomb Corporation is an eye health company in Canada and internationally. The company is headquartered in Vaughan, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?